简介
Dr Uhlen received his PhD in chemistry at the Royal Institute of Technology (KTH), Stockholm, Sweden in 1984. After a post-doc period at the EMBL in Heidelberg, Germany, he became professor at KTH in 1988. His research has resulted in more than 800 peer-reviewed publications leading to more than 120,000 academic citations with an h-index of 146 (Google Scholar). His focus in science has been technology- and data-driven research, involving protein science, antibody engineering, AI-based systems biology and precision medicine. A list of selected scientific achievements are shown below.
Dr Uhlen is member of the Royal Swedish Academy of Engineering Science (IVA), the Royal Swedish Academy of Science (KVA), the National Academy of Engineering (NAE) in USA and the European Molecular Biology Organization (EMBO). He was the President of the European Federation of Biotechnology (EFB) from 2015 to 2019 and he was the Vice-President of the Royal Institute of Technology (KTH) from 1999 to 2001. He is Honorary Doctor at Chalmers University, Sweden (2011) and Rouen University, France (2020).
Mathias Uhlen - 30 selected scientific achievements:
1. Cloning of the genes for protein A and protein G (1,2)
2. The use of biotin-streptavidin systems for molecular biology applications (3,4)
3. The concept of affinity tags for purification of proteins (5,6)
4. The concept of solid phase DNA sequencing (7,8)
5. Positive selection system for gene cloning (9)
6. EcoSec –secretion of proteins to the culture medium of E.coli (10)
7. The concept of in vivo half time extension using an Albumin-binding domain (11)
8. Pyrosequencing and the concept of sequencing by synthesis.(12,13,14)
9. Affibody and the concept of scaffold binders (15,16)
10. MabSekect SuRe and the concept of alkali-stable protein ligands (17)
11. Generation and use of antibodies to human cDNA clones. (18,19)
12. The Human Protein Atlas. (20,21)
13. Epitope mapping of antibodies. (22,23)
14. Antibodypedia – a portal for validated antibodies. (24)
15. IWGAV – international working group for antibody validation. (25,26)
16, The national infrastructure SciLifeLab (27)
17. The Tissue Atlas (28)
18. Correlation of RNA and protein levels. (29).
19. The Subcellular Atlas. (30)
20. The Brain Atlas (31)
21. The Pathology Atlas (32)
22. The Blood (Immune Cell) Atlas (33)
23. The Metabolic Atlas (34)
24. The Microbiome Atlas (35)
25. Quantitative targeted proteomics (36)
26. The Single Cell Atlas (37)
27. The Human Secretome (38,39)
28. Wellness profiling with multi-omics methods (40,41)
29. AI-based drug development for metabolic and neurodegenerative diseases. (42,43)
30. The Pan-Disease Blood Atlas (44,45).
Key references:
1. Uhlen et al (1984) J Biol Chem.
2. Olsson et al (1988) EMBO J
3. Ståhl et al (1988) Nucleic Acids Res.
4. Uhlen (1991) Nature
5. Löwenadler et al (1986) EMBO J.
6. Dahlson et al (2025) J Biotech
7. Hultman et al (1989) Nucl Acids Res.
8. Uhlen and Quake (2023) Trends Biotech.
9. Nilsson et al (1983) Nucleic Acids Res.
10. Abrahamsen et al (1986) Nucleic Acids Res..
11. Nygren et al (1998) J. Mol. Recogn.
12. Nyrén, Pettersson and Uhlen (1993) Anal. Biochem.
13. Ronaghi, Uhlen and Nyren (1998) Science
12. Nord et al (1997) Nature Biotechn.
13. Ståhl et al (2017) Trends in Biotechn.
17. Gulich et al (2000) J. Biotech.
18. Larsson et al (1996) J. Biotechn.
19. Agaton et al (2003) Mol. Cell. Proteomics
20. Nilsson et al (2005) Proteomics
21. Uhlen et al (2010) Nature Biotechn.
22. Forsström et al (2014)PLOS One
23. Sjöberg et al (2012) N Biotechn.
24. Alm et al (2014) J Proteome Res.
25. Uhlen et al (2016) Nature Methods
26. Edfors et al (2018) Nature Commun.
27. Travis (2010) Science
28. Uhlen et al (2015) Science,
29. Edfors et al (2016) Mol. Systems Biol.
30. Thul et al (2017) Science
31. Sjöstedt et al (2020) Science,
32. Uhlen et al (2017) Science
33. Uhlen et al (2019) Science
34 Robinson et al (2020) Science Signal.
35. Lee et al (2024) Genome Res.
36. Edfors et al (2014) Mol. Cell. Proteomics
37. Karlsson et al (2021) Science Advances
38. Uhlen et al (2019) Science Signal.
39. Tegel et al (2020) N. Biotechn.
40. Zhong et al (2020) Genome Medicine
41. Tebani et al (2020) Nature Comm..
42. Lam et al (2020) Drug Discovery Today
43. Mardinoglu et al (2025) Mol. Systems Biol.
44. Alvez et al (2023) Nature Commun.
45. Alvez et al (2025) Science
See full publication lists on Google Scholar or PubMed
.
